



PATENT
Attorney Docket **056707-5001-01**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gregory M. Glenn <i>et al.</i>)	Confirmation No. 4303
)	
Application No. 10/790,715)	Group Art Unit: 1644
)	
Filed: March 3, 2004)	Examiner: Yunsoo Kim
)	
For: Use of Penetration Enhancers and)	
Barrier Disruption Methods to Enhance)	
the Transcutaneous Immune Response)	

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97(c)(1) and (e)(1)

Pursuant to 37 C.F.R. 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed to the best of the undersigned's knowledge before a Notice of Allowance for the above-referenced application.

To the best of the undersigned's knowledge, each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. A copy of pages one and two of the European Office Action dated March 24, 2006 which issued in a related European Patent Application (European Patent Application No. 03007948.7) is enclosed for the Examiner's consideration. Accordingly, Applicants do not believe that a fee is due with the filing of this paper.


Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form. This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute prior art. If the Examiner applies any one of the documents as prior art against any claim in the application, and Applicants determine that the cited document does not constitute prior art under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **constructive petition for extension of time** in accordance with 37 C.F.R. 1.136(a)(3).

Dated: **June 19, 2006**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue
Washington, D.C. 20004
202-739-3000

Respectfully submitted,
Morgan, Lewis & Bockius LLP


Sally P. Teng
Registration No. 45,397



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449				Attorney Docket 056707-5001-01		Application No. 10/790,715			
				Applicants: Gregory M. Glenn <i>et al.</i>				Page 1 of 1	
				Filing Date: March 3, 2004		Group Art Unit: 1644			
U.S. PATENT DOCUMENTS									
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date		
FOREIGN PATENT DOCUMENTS									
		Document No.	Date	Country	Class	Sub-Class	Translation		
	aa	WO 96/14074	05/17/1996	PCT					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)									
	ab	Vaccine Adjuvants – Preparation Methods and Research Protocols, Edited by D.T. O’Hagan, Humana Press, Totowa, N.J. 2000, pp. 1-5.							
Examiner				Date Considered					
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									